Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

ChitogenX Inc C.CHGX

Alternate Symbol(s):  CHNXF

Healthcare Biotechnology
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of orthopaedic and sports medicine surgeries in Canada. It develops Ortho-R, a biopolymer for rotator cuff repair; and Ortho-M, a biopolymer for meniscus repair. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.


CSE:CHGX - Post by User

ChitogenX Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2269)
•••
  • Betteryear2X
Post by Betteryear2on May 04, 2022 3:32pm
260 Views
Post# 34656177

RECEIVES KEY U.S. COMPOSITION AND METHOD PATENT CSE: ORTH

RECEIVES KEY U.S. COMPOSITION AND METHOD PATENT CSE: ORTH
  • New patent issued by U.S. Patent and Trademark Office to protect core IP until 2035
     
  • Positions Company as leading player in the dynamic regenerative medicine market
     
  • Enables delivery of PRP in soft tissue repair surgery in a proprietary way

MONTREAL, May 4, 2022 /PRNewswire/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) ("Ortho" or the "Company"), a clinical-stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today that the United States Patent and Trademark Office (the "USPTO") has issued a patent related to the Company's ORTHO-R soft tissue repair platform
 

https://www.prnewswire.com/news-releases/ortho-regenerative-technologies-receives-key-us-composition-and-method-patent-for-ortho-r-soft-tissue-repair-platform-301539419.html

 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities